hit counter
Aptevo Therapeutics Inc. (APVO) Stock News Sentiment & Price - Sentifly
APVO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aptevo Therapeutics Inc. (APVO)

USA
Biotechnology
NASDAQ
APVO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
APVO Latest news
Accesswire
Neutral
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
2021-11-11 16:45

Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society of Immunotherapy Cancer's (SITC) 36th Annual Meeting, taking place virtually and in-person November 12- 14, 2021 in Washington D.C. The poster highlights preclinical datasets as an overview of the potential indication landscape, mechanism of action and the efficacy profile of ALG.APV-527, which support the molecule's progression into the clinic.

Accesswire
Neutral
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
2021-11-11 08:30

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the presentation of preclinical data for APVO603, the Company's bispecific antibody targeting 4-1BB (CD137) and OX40 (CD134), at the Society for Immunology in Cancers (SITC) 2021 Annual Meeting. Poster #795 entitled, "APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIR™ technology designed to deliver a conditional T cell/NK response against solid tumors," will be presented and displayed on-site on Saturday, November 13th in Washington, D.C.

Accesswire
Neutral
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
2021-10-27 08:05

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021, with a Poster Presentation. The poster abstract was selected as one of the best abstracts and included into the Congress program as an oral presentation as well.

Accesswire
Neutral
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
2021-10-26 08:05

SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the peer-reviewed journal Cancers published results of the Company's research on mitigation of the risk of cytokine release syndrome (CRS) as well as its effective management in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are treated with APVO436, a bispecific antibody that has been engineered to redirect patients' immune system against their cancer cells. Dr. Fatih Uckun, a leukemia expert and Chief Clinical Advisor to Aptevo, is the lead author of the newly published article.

Accesswire
Neutral
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
2021-09-28 08:05

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-risk adult MDS patients SEATTLE, WA / ACCESSWIRE / September 28, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the prestigious medical journal Frontiers in Aging, published a peer-reviewed article by Fatih Uckun, M.D., Ph.D., Chief Clinical Advisor at Aptevo who is coordinating the APVO436 clinical development program.

Accesswire
Neutral
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
2021-08-17 08:05

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was published in the prestigious oncology journal Cancers SEATTLE, WA / ACCESSWIRE / August 17, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the publication of a peer-reviewed research article in the prestigious oncology journal Cancers . The research article reports the results of a multi-institutional Phase 1 clinical study of Aptevo's lead leukemia drug candidate APVO436 in 46 adult patients with relapsed or refractory AML or MDS.

Accesswire
Neutral
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
2021-08-12 08:05

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results and business highlights for the quarter ended June 30, 2021. Business Highlights Announced results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).

Accesswire
Neutral
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
2021-07-16 08:05

SEATTLE, WA / ACCESSWIRE / July 16, 2021 /?Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today?announced that Dr. Jane Gross, Senior Vice President of Research and Development and Chief Scientific Officer of Aptevo, will give a presentation and participate in a live interactive panel discussion at the Cambridge Health Institute PEGS Virtual Conference being hosted from Monday, July 19, 2021 - Thursday, July 22, 2021. Dr. Gross' talk, entitled "Generating Immuno-Modulatory Bispecific Therapeutic Candidates for the Treatment of Hematologic and Solid Tumors," will occur on Monday, July 19, 2021 at 11:25 am Eastern time.

Accesswire
Neutral
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
2021-06-29 08:05

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies today announced that the company has been added to the Russell Microcap® Index at the conclusion of the 2021 annual reconstitution. Aptevo's inclusion in the index became effective after the US market opened yesterday, June 28, 2021.

Zacks Investment Research
Positive
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?
2021-06-15 08:16

Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Loading more news...